News Column

Nuvilex Primed to Succeed Where Others Have Failed

Jun 25 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 06/25/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that as Nuvilex (OTCQB: NVLX) continues on to the next phase of development following successful Phase II clinical trials to treat advanced inoperable pancreatic cancer, we may perhaps be witnessing the dawn of a new universal cancer therapy potentially worth billions of dollars.

The proliferation of early cancer screening and the cessation of smoking have been universal methods which have been used in recent years to prevent cancer. Yet, despite spending over $100+ billion in funding cancer research and development projects by private industry and quasi-government organizations, there is no universally approved therapy. Moreover, most of the treatments today are akin to poison, as they are toxic to healthy cells as well as cancer cells and often cause such severe side effects that some patients opt out of the treatment altogether.

Conversely, the Nuvilex delivery platform and therapy is unique relative to existing therapies. Therefore, it may ultimately be used to treat multiple forms of cancer given the mechanism of action, the highly concentrated and targeted placement concept, and low toxicity associated with the therapy.

Nuvilex's patented live-cell encapsulation technology enables the targeted placement and delivery of any cell type into the body after enclosing the cells inside tiny beads. This platform does not encapsulate drugs, but live cells. Depending on the cell type placed into the beads, or encapsulated, these cells enable continuous and/or controlled production and release of targeted therapeutic molecules via an innovative delivery system. The capsules enclosing the live cells are made largely from cellulose a bio-inert, non-toxic, biocompatible material that protects the encapsulated cells from attack by the body's defense mechanisms. At the same time, the beads provide a microenvironment that enables encapsulated cells to survive for long periods of time, which is a major advantage over others' encapsulation technologies and critical for future storage and mass deployment.

By using the technology, it is possible to create small cell-based factories that can be made to 1) convert inactive drugs into the active ones, 2) produce bioactive therapeutic substances, and for numerous other applications. In the case of the drug-converting "factories" and their use in cancer therapy, cells inside the capsules are deployed directly at the tumor site to create a continuous high concentration of active cancer fighting molecules (active drug) and in effect provide a dramatically elevated dose of active drugs right where they're needed, the tumor.

Once successful with one therapy such as inoperable pancreatic cancer, it is likely Nuvilex will target breast cancer next, as it moes closer to becoming a universal cancer therapy.

A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.



Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools